The genomic characterization of different progression patterns in advanced lung cancer (LC) patients upon immune checkpoint inhibitor (ICI) treatment.

e21653Background: Hyperprogressive disease (HPD), characterized by a rapid increase in tumor growth rate (TGR), has been reported in 13.8% NSCLC patients (pts) treated with ICI. Besides, 10.4% of N...